Lupin receives FDA approval for biosimilar Armlupeg
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
Subscribe To Our Newsletter & Stay Updated